Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ΣΦ-4005
- Development stage
- Preclinical
- Lead developer
- Sigmapharm Laboratories
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ΣΦ-4005 is an internal development code used by Sigmapharm Laboratories for a pharmaceutical candidate in their pipeline. Sigmapharm, a company specializing in generic and specialty pharmaceuticals, lists this code in its regulatory submission tracker for products being prepared for Abbreviated New Drug Application (ANDA) or New Drug Application (NDA) submissions. The specific identity of the drug, including its active pharmaceutical ingredient (API), molecular target, and therapeutic indication, has not been publicly disclosed. The program is characterized by Sigmapharm as having significant barrier-to-entry properties, which may include technical challenges related to formulation, stability, bioavailability, or legal challenges involving patent litigation.
Beyond the preview
Go deeper on ΣΦ-4005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ΣΦ-4005.